ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, patients received the agent via subcutaneous injection every three weeks ...
Eisai & Nuvation Bio ink exclusive licensing pact for taletrectinib in Europe and additional countries outside US, China and Japan: Tokyo Thursday, January 15, 2026, 10:00 Hrs [IS ...
Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...
Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...
ImmunityBio extended its winning streak to an 8th straight day on Tuesday, jumping 8.88 percent to finish at $2.82 apiece as ...
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation ...
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.
AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...
An insurance company decided that profits matter more than the life of a man who spent his career protecting this city,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback